NasalSeasonal allergic rhinitisAdult: As 0.6% spray: 2 sprays into each nostril bid. Child: 6-11 year 1 spray into each nostril bid.
OphthalmicAllergic conjunctivitisAdult: As 0.1% soln: 1 drop in the affected eye(s) bid at an interval of 6-8 hr. As 0.2% soln: 1 drop in the affected eye(s) once daily. Child: ≥3 yr Same as adult dose.
|
Not intended for contact lens-related irritation (ophth). Patient w/ other nasal disease. Pregnancy and lactation.
|
Headache, somnolence. Symptoms similar to cold syndrome and pharyngitis, blurred vision, ocular burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid oedema, or ocular pain or pruritus. Nasal: Bitter taste, epistaxis, pyrexia, rash, nasal ulceration and septal perforation, pharyngolaryngeal pain, postnasal drip, cough, UTI, upper resp tract infection.
|
|
May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Ophth: Remove contact lenses prior to eye admin. Reinsert contact lenses 10 min after admin. Do not wear contact lenses if eyes are red. Improper handling may contaminate soln w/ bacteria that may cause ocular infections. Tip of the dispensing container should not be in contact w/ eye, eyelids or surrounding structures.
|
Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa.
|
Symptoms: Drowsiness in adults and, initially, agitation and restlessness, followed by drowsiness in childn. Management: Symptomatic or supportive treatment.
|
May result in additive CNS depression w/ CNS depressants.
|
Concomitant use w/ alcohol may result in additive CNS depression (nasal).
|
Description: Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers. Onset: 30 min (nasal). Pharmacokinetics: Absorption: Ophth: Minimal. Bioavailability: 57% (nasal). Time to peak plasma concentration: 15 min to 2 hr (nasal). Distribution: Plasma protein binding: Approx 55% (mainly albumin). Metabolism: Not extensively metabolised. Excretion: Via urine (60-70% as unchanged drug); faeces (approx 17%). Elimination half-life: 8-12 hr.
|
|
|
Anon. Olopatadine (Nasal) Drug Information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/03/2014. Anon. Olopatadine (Ophthalmic) Drug Information. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/03/2014. Buckingham R (ed). Olopatadine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/03/2014. McEvoy GK, Snow EK, Miller J et al (eds). Olopatadine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/03/2014. Patanase Spray, Metered (Alcon Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/03/2014.
|